Vertex Pharmaceuticals Incorpo

VRTX 
(NASDAQ) 
 
$ 183.06
Updated 01:00:00
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 688,997
High $ 187.89
Low $ 182.16
Open $ 187.70
ISIN
Prev close $ 187.84
# of shares 255.66M
Market cap 46,801M USD
Intraday

Market closed
Vertex Pharmaceuticals Incorpo
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  183.06 -2.7% Stock price decreasing -5.6% Stock price decreasing 14.2% Stock price increasing 3.0% Stock price increasing 16.2% Stock price increasing
Powered by TradingView

News about Vertex Pharmaceuticals Incorpo

  • English
  • Regulatory news
31 Jan
 
04 Jan
 
14 Nov
 
10 Oct
 
10 Aug
 
30 May
 
10 May
 
09 Mar
 

Company profile

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, influenza, and other rare diseases.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:11:13
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB4 - 2019-02-22 10:11:13 - 2019-02-22 09:11:13 - 1000 - Website: OKAY